Mandatory folic acid fortification and the science of \u27sociality\u27 by Lawrence, Mark
Deakin Research Online 
 
This is the published version:  
 
Lawrence, Mark 2006, Mandatory folic acid fortification and the science of 'sociality', Public 
health nutrition, vol. 9, no. 7, pp. 827-828. 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30013349 
  
Reproduced with the kind permission of the copyright owner. 
 
Copyright : 2006, The Author 
Letter to the Editor
Mandatory folic acid fortification and the science of ‘sociality’
Sir,
In his recent Out of the Box column, Geoffrey Cannon1
comments that mandatory folic acid fortification (MFAF) of
food is an ‘outstanding example’ where nutrition as a
classic biological science can be a science of ‘sociality’, i.e.
its findings translated to inform policy to benefit society as
a whole.
However, MFAF is a more complex policy debate than
often is recognised.
According to the Codex Alimentarius Commission, a
national MFAF policy is indicated where there is scientific
evidence of a population-wide deficiency of folate and
related conditions such as anaemia are endemic2. In such
circumstances MFAF is unambiguously a nutrition policy
in the interests of society as a whole.
However, Geoffrey Cannon is referring to MFAF in the
context of a policy response to evidence of the
relationship between an increased dietary folate intake
and reduced risk of neural tube defects (NTDs). Although
the biological mechanism and precise dose required for
folate to exert its protective effect in reducing NTD risk are
uncertain, it is thought to be a compensation for a
congenital defect in certain at-risk individuals who have
limited ability to metabolise folate3. The protective effect is
consistent with a therapeutic-type response and is exerted
in a dose–response relationship requiring substantially
higher amounts (up to 4mg day21 for maximum effect)4
than presently consumed as folate from foods, rather than
addressing a conventional folate deficiency.
The central dilemma concerning prophylactic folic acid
use here is that approximately half of all pregnancies are
unplanned and by the time many women are aware they
are pregnant the neural tube will have closed. Therefore
MFAF is an appealing policy because it ensures passive
exposure by the target group, requiring no behaviour
change during the critical periconceptual period. Also, it is
equitable5; all women regardless of background or
circumstances will be exposed.
Yet, because the policy intervention is non-discriminat-
ing, it will expose all children, teenagers, adults and older
people who consume the fortified food(s) to raised levels
of synthetic folic acid. In this context, MFAF represents a
‘mismatch’ between the genetic nature of the problem and
the population-wide scope of the policy solution6. The
existence of this mismatch is relevant because it casts
doubts over whether the interests of either the target
group (women of childbearing age) or the population in
total are best served by such a policy.
For the target group, the benefit of MFAF in terms of
reduced incidence of NTDs is clear. However, a dietary
folate intake of 1mg day21 for adults is the upper level of
safety in many countries, especially due to concerns about
possible masking of the symptoms of vitamin B12
deficiency7. In recognition of this concern, policy-makers
have had to curtail the extent of fortification and this in
turn has restricted the potential benefit. For example, Food
Standards Australia New Zealand has proposed a level of
mandatory fortification at 80–180mg of folic acid per 100 g
of breads8. Whereas at this level it is estimated the dietary
folate intake of only a small proportion of the population
will exceed the upper level of safety, it is also estimated
that just 26 of the approximate 300–350 affected
pregnancies in Australia each year will be prevented8,
i.e. just 8% of the total. In addition, the possible
relationship between raised exposure to folic acid and
increased twinning remains a health concern9.
For the population in total, additional folic acid intake
has been hypothesised to be advantageous to the wider
population – by lowering plasma homocysteine levels
and thereby reducing cardiovascular disease risk and by
improving cognitive function. However, the findings of
several recent studies now refute these hypotheses and
even suggest that elevated folic acid status may be a
potential risk factor for these conditions10–13. Moreover,
the findings of other recent trials indicate that raised
exposure to folic acid is a potential risk for colorectal
cancer14 and breast cancer15.
Also, aUS study identifiedunmetabolised folic acid in the
circulation of 78% of postmenopausal women and showed
that there was an inverse relationship between this and a
measure of immunity (natural killer cell cytotoxicity)16.
This is a particular concern because, following the
introduction of MFAF in the USA, folic acid intake is
estimated to have been twice the projected average
increase in intake17. As a result, the mean serum folate
levels in all age and sex groups have more than doubled18.
Rather than providing the outstanding example that
Geoffrey Cannon suggests, MFAF serves to illustrate the
scientific and ethical uncertainties that can arise when
translating nutrition evidence relating to specific groups to
food policies that have a population-wide impact. Clearly
there are benefits from MFAF for at-risk individuals, but it
remains uncertain whether these benefits outweigh the
potential risks. For society as a whole there is an ethical
dimension to consider in balancing the interests of at-risk
individuals with the interests of the population in total.
Where MFAF policy exists, adequate monitoring is
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essential so that potential risks and benefits can be
determined for the target group and society as a whole.
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